A5041637994- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Chronic Lymphocytic Leukemia Research
- Pancreatic function and diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Gestational Diabetes Research and Management
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Diet, Metabolism, and Disease
- Diabetes and associated disorders
- Health and Lifestyle Studies
- Sensory Analysis and Statistical Methods
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Novo Nordisk (Denmark)
2010-2024
Concord Consortium
2019
Alberta Bible College
2016
IMPORTANCE Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities.Few safe, effective weight-management drugs are currently available.OBJECTIVE To investigate efficacy safety liraglutide vs placebo for weight management in adults with overweight or obesity diabetes.DESIGN, SETTING, AND PARTICIPANTS Fifty-six-week randomized (2:1:1), double-blind, placebo-controlled, parallel-group trial 12-week observational off-drug follow-up period.The study was conducted at 126...
Objective To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in responders (ERs) nonresponders (ENRs). Methods Using pooled data from the SCALE Obesity Prediabetes Diabetes trials, of ≥4% 16 weeks best predicted after weeks. Weight changes cardiometabolic risk factors health‐related quality life were evaluated ERs (≥4% 16) ENRs (<4% completing weeks’ treatment. Results Proportions ERs/ENRs 77.3%/22.7%...
Abstract Aim To evaluate the efficacy and safety of once‐weekly subcutaneous semaglutide, a glucagon‐like peptide‐1 (GLP‐1) analogue, versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes (T2D) multiregional clinical trial. Materials Methods In 30‐week, randomized, double‐blind, double‐dummy, active comparator SUSTAIN China trial, 868 adults T2D inadequately controlled on (HbA1c 7.0%‐10.5%) were randomized receive semaglutide 0.5 mg (n = 288), 1.0 290) or 100...
Abstract Aims The aim of this study was to compare long‐term safety and efficacy the basal insulin analogue degludec with glargine in insulin‐naive subjects Type 2 diabetes. Methods This open‐label trial included a 52‐week core period followed by extension. Participants were randomized 3:1 once‐daily or glargine, administered metformin ± dipeptidyl peptidase‐4 inhibitors. Basal titrated target pre‐breakfast plasma glucose 3.9–4.9 mmol/l. Results At end treatment (104 weeks), mean HbA 1c...
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and (IAsp: 30%). Here, we compare the efficacy safety IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), biphasic IAsp 30 (BIAsp 30).Sixteen-week, open-label, randomised, treat-to-target trial.Insulin-naive subjects with type 2 diabetes (18-75 years) HbA1c 7-11% were randomised to twice-daily (n=61), AF (n=59) or BIAsp (n=62), all in combination metformin. was administered...
OBJECTIVE A recent randomized trial compared prandial insulin aspart (IAsp) with human in type 1 diabetic pregnancy. The aim of this exploratory analysis was to investigate the incidence severe hypoglycemia during pregnancy and compare women enrolled preconception early RESEARCH DESIGN AND METHODS IAsp administered immediately before each meal 30 min 99 subjects (44 55 insulin) randomly assigned 223 (113 for 110 (&lt;10 weeks). NPH basal insulin. Severe (requiring third-party assistance)...
The aim of this trial was to evaluate the efficacy and safety combination once-daily insulin detemir (IDet) sitagliptin (SITA) versus SITA ± sulphonylurea (SU), both in with metformin (MET) insulin-naive subjects.In a 26-week, open-label, randomized, parallel-group study type 2 diabetes, subjects concomitantly treated MET second oral antidiabetic drug (OAD) were randomized 1 : IDet + or SU. All continued treatment, those SU if Efficacy endpoints included glycosylated haemoglobin (HbA1c),...
Abstract Aims To investigate, in a 26‐week, open‐label, randomized, treat‐to‐target trial, the efficacy and safety of insulin degludec/insulin aspart ( ID egAsp) once daily vs glargine IG lar) adults with Type 2 diabetes, inadequately controlled on basal insulin. Methods Participants were randomized (1:1) to egAsp or lar combination existing oral antidiabetic drugs. was administered main evening meal largest day (agreed at baseline); dosing time maintained throughout trial. titrated their...
Aim The efficacy and safety of insulin degludec ( IDeg ), a new basal with an ultra‐long duration action, was compared to sitagliptin (Sita) in 26‐week, open‐label trial. Methods Insulin‐naïve subjects type 2 diabetes [n = 458, age: 56 years, duration: 7.7 glycosylated haemoglobin HbA1c ): 8.9% (74 mmol/mol)] were randomized (1 : 1) once‐daily or Sita (100 mg orally) as add‐on stable treatment 1 oral antidiabetic drugs OADs ). Results Superiority improving fasting plasma glucose FPG )...
The efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to diet exercise, was evaluated in racial subgroups. This post hoc analysis pooled data from five double‐blind randomized, placebo‐controlled trials conducted 5325 adults with either a body mass index ( BMI ) ≥27 kg/m 2 plus ≥1 comorbidity or ≥30 . Statistical interaction tests possible treatment effect differences between subgroups: white (4496, 84.4%), black/African‐American (550, 10.3%), Asian (168, 3.2%) other (111,...
The journal and the authors apologise for errors in Table 2 of this article that was published August issue (vol 167 , pp 287–294 ). n values were incorrectly published. correct are presented below table is full below. Observed mean changes from baseline HbA1c, FPG body weight. Data observed as ( s.d .) all randomised subjects (full analysis set). Baselinea Week 16b Change HbA1c (%) IDegAsp 61 8.5 (1.2) 6.7 (1.0) −1.8 (1.1)c AF 59 (0.9) 6.6 (0.6) −1.9 BIAsp 30 62 8.6 (0.7) (0.9)c (mmol/l)...
Once-weekly (OW) subcutaneous (s.c.) semaglutide is an injectable glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. This trial was designed to assess pharmacokinetics, safety and tolerability OW s.c. in healthy Chinese subjects. In this single-centre, randomised, double-blind, placebo-controlled trial, 36 subjects were randomised 0.5 mg (n = 12), 1.0 or placebo 12). Treatment (semaglutide placebo) blinded subjects, investigators sponsor. The primary...
The glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved as an oral formulation for the treatment of type 2 diabetes. This study aimed to confirm bioequivalence between a new, second-generation (2G) (1.5, 4 and 9 mg) initially first-generation (1G) (3, 7 14 mg). was randomised, multicentre, open-label, full replicate crossover 2G 1G formulations at steady-state (SS) in healthy participants (NCT05227196). Participants were recruited three groups. In each group, randomised one two...
Liraglutide at doses up to 1.8 mg in combination with OADs and/or basal insulin is approved for the treatment of T2D. The randomized, double-blind, placebo-controlled trial SCALE Diabetes (NCT01272232) investigated efficacy and safety liraglutide 3.0 mg, as adjunct diet exercise, weight management obese/overweight adults
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
This 3-year trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet and exercise (D&E), in delaying onset T2D (primary endpoint) adults with prediabetes obesity (BMI ≥30 kg/m2) or overweight (≥27 comorbidities.